JP2024518947A5 - - Google Patents
Info
- Publication number
- JP2024518947A5 JP2024518947A5 JP2023568726A JP2023568726A JP2024518947A5 JP 2024518947 A5 JP2024518947 A5 JP 2024518947A5 JP 2023568726 A JP2023568726 A JP 2023568726A JP 2023568726 A JP2023568726 A JP 2023568726A JP 2024518947 A5 JP2024518947 A5 JP 2024518947A5
- Authority
- JP
- Japan
- Prior art keywords
- administered
- agent
- composition according
- weeks
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163186569P | 2021-05-10 | 2021-05-10 | |
| US63/186,569 | 2021-05-10 | ||
| PCT/US2022/028135 WO2022240688A1 (en) | 2021-05-10 | 2022-05-06 | Dosing regimen for combination therapy targeting dll3 and pd-1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024518947A JP2024518947A (ja) | 2024-05-08 |
| JP2024518947A5 true JP2024518947A5 (enExample) | 2025-05-21 |
Family
ID=84029376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023568726A Pending JP2024518947A (ja) | 2021-05-10 | 2022-05-06 | Ｄｌｌ３及びｐｄ－１を標的とする組み合わせ療法のための投与レジメン |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240317856A1 (enExample) |
| EP (1) | EP4337252A4 (enExample) |
| JP (1) | JP2024518947A (enExample) |
| KR (1) | KR20240006585A (enExample) |
| CN (1) | CN117377488A (enExample) |
| AU (1) | AU2022273509A1 (enExample) |
| CA (1) | CA3217141A1 (enExample) |
| CL (1) | CL2023003357A1 (enExample) |
| IL (1) | IL307646A (enExample) |
| MX (1) | MX2023013227A (enExample) |
| TW (1) | TW202309092A (enExample) |
| WO (1) | WO2022240688A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12247060B2 (en) | 2018-01-09 | 2025-03-11 | Marengo Therapeutics, Inc. | Calreticulin binding constructs and engineered T cells for the treatment of diseases |
| WO2020010250A2 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| JP7579795B2 (ja) | 2019-02-21 | 2024-11-08 | マレンゴ・セラピューティクス，インコーポレーテッド | ＮＫｐ３０に結合する抗体分子およびその使用 |
| AU2020226893B2 (en) | 2019-02-21 | 2025-02-27 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| WO2021138474A2 (en) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| EP4482586A1 (en) * | 2022-02-23 | 2025-01-01 | Amgen Inc. | Cancer treatment targeting dll3 |
| KR20250116698A (ko) * | 2022-12-08 | 2025-08-01 | 암젠 인크 | Dll3-발현 암의 치료 방법 |
| CN121620371A (zh) * | 2023-05-19 | 2026-03-06 | 勃林格殷格翰国际公司 | T细胞衔接蛋白在治疗癌症中的用途 |
| CN120168667B (zh) * | 2025-03-18 | 2026-04-14 | 中国科学院近代物理研究所 | 一种多肽在制备dll3过度表达的肿瘤的特异性靶向分子探针中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI793062B (zh) * | 2015-07-31 | 2023-02-21 | 德商安美基研究（慕尼黑）公司 | Ｄｌｌ３及ｃｄ３抗體構築體 |
| EA039859B1 (ru) * | 2015-07-31 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| EP3337517A4 (en) * | 2015-08-20 | 2019-04-17 | Abbvie Stemcentrx LLC | ANTI-DLL3 ANTIBODY AGGREGATE CONJUGATES AND METHOD OF USE |
| CR20200539A (es) * | 2018-04-10 | 2021-07-01 | Kite Pharma Inc | Receptores quiméricos de dll3 y métodos para su uso |
| TWI848953B (zh) * | 2018-06-09 | 2024-07-21 | 德商百靈佳殷格翰國際股份有限公司 | 針對癌症治療之多特異性結合蛋白 |
-
2022
- 2022-05-06 WO PCT/US2022/028135 patent/WO2022240688A1/en not_active Ceased
- 2022-05-06 EP EP22808092.5A patent/EP4337252A4/en active Pending
- 2022-05-06 KR KR1020237041314A patent/KR20240006585A/ko active Pending
- 2022-05-06 CN CN202280031401.6A patent/CN117377488A/zh active Pending
- 2022-05-06 CA CA3217141A patent/CA3217141A1/en active Pending
- 2022-05-06 AU AU2022273509A patent/AU2022273509A1/en active Pending
- 2022-05-06 IL IL307646A patent/IL307646A/en unknown
- 2022-05-06 US US18/289,317 patent/US20240317856A1/en active Pending
- 2022-05-06 MX MX2023013227A patent/MX2023013227A/es unknown
- 2022-05-06 JP JP2023568726A patent/JP2024518947A/ja active Pending
- 2022-05-10 TW TW111117458A patent/TW202309092A/zh unknown
-
2023
- 2023-11-10 CL CL2023003357A patent/CL2023003357A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023501375A5 (enExample) | ||
| JP2025508786A5 (enExample) | ||
| CN104271135B (zh) | 在要求减少施用容量的患者中治疗苯达莫司汀响应性状况的方法 | |
| JP2022525149A5 (enExample) | ||
| JP2011511071A5 (enExample) | ||
| JP2024129140A5 (enExample) | ||
| JP2018514510A5 (enExample) | ||
| JP2019530713A5 (enExample) | ||
| JPWO2020250915A5 (enExample) | ||
| JP2021535161A5 (enExample) | ||
| Snell et al. | A randomized, double‐blind, placebo‐controlled, multicenter study of rabbit ATG in the prophylaxis of acute rejection in lung transplantation | |
| JP2020158544A5 (enExample) | ||
| JP2022532356A5 (enExample) | ||
| JP2022544485A5 (enExample) | ||
| JP2024542682A5 (enExample) | ||
| Moe et al. | High dose methotrexate in acute lymphocytic leukemia in childhood | |
| Anttinen et al. | Intra-articular triamcinolone hexacetonide and osmic acid in persistent synovitis of the knee | |
| Cornwell et al. | Hypersensitivity reactions to IV melphalan during treatment of multiple myeloma: Cancer and Leukemia Group B experience | |
| JP2022514561A5 (enExample) | ||
| JP2023521853A5 (enExample) | ||
| IL317954A (en) | Treatment of hematological malignancies with galectin-9 inhibitory antibodies | |
| RU2394596C2 (ru) | Комбинированная терапия радиоактивно меченым антителом анти-cd20 при лечении в-клеточной лимфомы | |
| Beisel | Alterations in hormone production and utilization during infection | |
| CA1189792A (en) | Adrenosteroid composition and method for the treatment of shock by infusional therapy | |
| US20250019441A1 (en) | Treatment of cancer with anti-ilt2 antibodies |